Hardy sees fertile ground in D.C. for Biomarin’s rare disease strategy

With its first acquisition in over 10 years, Biomarin’s strengthening balance sheet and renewed corporate strategy mean the genetically defined disease company is well positioned to add its pipeline via dealmaking, with the takeout of Inozyme the first of a planned string of deals.

In an exclusive interview with BioCentury, President and CEO Alexander Hardy said that Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is well-placed to be the partner of choice for companies developing therapies for rare or ultra-rare genetically defined diseases — especially in this market and policy environment. ...